Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Kiadis Pharma B.V.

Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company focused on the development of innovative and potentially life-saving therapies for patients with late stage blood cancers and related disorders, an area of significant unmet medical need. Kiadis Pharma's lead product is ATIR™, a T-cell immunotherapy based medicinal product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors. Kiadis Pharma is collaborating with internationally renowned centers in Europe and North America for the successful development and manufacturing of ATIR™. Kiadis Pharma is working under a GMP manufacturing license and GMP certificate for its Quality Control laboratory. Kiadis Pharma is supported by a strong group of leading international investors including LSP, DFJ Esprit, Alta Partners, Quest for Growth, NOM and MedSciences Capital. Kiadis Pharma is based in Amsterdam, The Netherlands. *

 

Period Start 2006-11-28 merged
  Group Kiadis (Group)
  Predecessor Kiadis B.V.
Products Industry cancer drug
  Industry 2 ATIR™ (Kiadis)
     
Region Region Groningen
  Country Netherlands
  Street 6–8 Zernikepark
  City 9747AN Groningen
  Tel +31-50-547-4270
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: 
     
   
Record changed: 2020-08-19

Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for Kiadis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top